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 especially in infantile spasms in the setting of 
tuberous sclerosis) (11–13). Therefore, most 
recently the treatment of WS with valproate 
has been overtaken and overlooked (14, 15).
Overall, the treatment strategies in WS 
[either the first-line treatments (e.g., ACTH 
and vigabatrin) or the more classical non-
golden treatments (e.g., valproate or other 
newer anticonvulsants)] are based on the 
assumption that an early initiation of ther-
apy coupled with a rapid control of seizures 
in these patients may prevent the arrest or 
the decline in cognitive development.
However, the spectrum of disorders asso-
ciated to clinical spasms with onset in infancy 
is wider than previously thought and is cur-
rently comprised under the umbrella term 
of Infantile Spasms syndrome (ISs), which 
defines an epileptic syndrome (occurring in 
children younger than 1 year – rarely older 
than 2 years), with clinical (epileptic: i.e., 
associated to an epileptiform EEG) spasms 
usually occurring in clusters whose most 
characteristic EEG finding is hypsarrhyth-
mia (the spasms are often associated with 
developmental arrest or regression). WS 
refers to a form (a subset) of ISs, character-
ized by the combination of clustered spasms 
and hypsarrhythmia on an EEG. Additional 
(less common) phenotypes falling within 
the ISs include the so-called infantile spasms 
single-spasm variant (ISSV: in which spasms 
may occur singly rather than in clusters), 
hypsarrhythmia without infantile spasms 
[HWIS: in which hypsarrhythmia can be 
(incidentally) recorded without any evi-
dence of clinical spasms], and infantile 
spasms without hypsarrhythmia (ISW: in 
which typical clinical spasms may manifest 
in absence of hypsarrhythmia) [reviewed in 
Lux and Osborne (11)]. There is a growing 
evidence that ISs and related phenotypes 
may result, besides from acquired events, 
from disturbances in key genetic pathways of 
brain development: specifically, in the gene 
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The recent article by Chandra et al. (1), 
published in Frontiers in Neurology, on the 
treatment of West syndrome (WS) by using 
valproate as monotherapy, prompted us to 
rethink about the past and present treat-
ment strategies and the outcome in this 
severe epileptic syndrome.
Even though the study by Chandra et al. 
(1) leaves some unsolved issues regarding 
the lack of demonstration of hypsarrhyth-
mia in 70% of their cases, the long-term 
follow-up of cognitive profiles in the whole 
group, an extensive etiological work-up and 
the alternative use of new therapeutic drugs 
such as vigabatrin, it provides the scientific 
community with successful short-term 
results in 36/91 (40%) of their treated WS 
patients who showed “… a greater than 80% 
decrease in the number of spasms or com-
plete cessation.”
Historically, some previous studies in 
children with WS, which employed val-
proate as monotherapy, proved effective 
in controlling either hypsarrhythmia and/
or the epileptic spasms (2–6). Besides val-
proate, zonisamide, topiramate, and nitraz-
epam (as monotherapy or in combination) 
showed good responses (ranging from 20 
to 35% of treated patients) in WS (7–9). 
More effective, however, has proven the 
short-term treatment with hormonal ther-
apy (i.e., by using the adrenocorticotropic 
hormone ACTH), which has been reported 
to succeed in 60–80% of the infants with 
WS treated (10). Therefore, nowadays the 
first-line treatment of WS and more in gen-
eral of infantile spasms includes ACTH as 
well as vigabatrin (the latter being effective 
regulatory network of GABAergic forebrain 
dorsal-ventral development, and abnormali-
ties in molecules expressed at the synapse 
(16). Notably, children with these genetic 
associations also have phenotypes beyond 
epilepsy, including dysmorphic features, 
autism, movement disorders, and systemic 
malformations (16). In this respect, the ISs 
and related phenotypes, could be regarded as 
a (peculiar) type of neurological manifesta-
tion underlying the involvement of many 
different neuronal/interneuronal networks 
and, accordingly, the cognitive delay or arrest 
regarded as a (genetically predetermined) 
part of the (more or less severe) phenotype, 
which in turn is related to the type or severity 
of mutation or to the protein/molecule and/
or regulatory network involved.
For all the above reasons, the results of 
Chandra et al. (1) highlight the multifac-
eted aspects of the spectrum of disorders 
associated to clinical spasms (i.e., good 
response to a classical anticonvulsant in 
the era of newer drugs and other-than 
valproate first-line treatments) and the 
prevalent role that etiological events 
could play in pre-programing the cogni-
tive and behavioral outcomes in the set-
ting of ISs (16). In this respect, without 
forgetting the current first-line treatment 
strategies for ISs and related phenotypes, 
we should also look with less strict thera-
peutic boundaries at patients with clini-
cal spasms as in the near future the gold 
standard could be the development of new 
therapies (with new or old molecules) that 
simply target specific pathways of patho-
genesis, as currently occurs in tuberous 
sclerosis (17, 18).
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